---
layout: default
title: Carboplatin
description: "Carboplatin çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚é«˜è­‰æ“šç­‰ç´š L2ï¼ŒåŒ…å« 10 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: é«˜è­‰æ“šç­‰ç´š (L1-L2)
nav_order: 40
evidence_level: L1
indication_count: 10
---

# Carboplatin

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L2</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>10</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Carboplatinï¼šå¾åŒ–ç™‚åŸºçŸ³åˆ°å¥³æ€§ä¹³è…ºç™Œçš„æ–°æ¢ç´¢

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Carboplatin å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Carboplatin æ˜¯é‰‘é¡æŠ—ç™Œè—¥ç‰©ï¼Œå·²å»£æ³›ç”¨æ–¼å¤šç¨®ç™Œç—‡æ²»ç™‚ã€‚
TxGNN æ¨¡å‹é æ¸¬å®ƒå¯èƒ½å°**å¥³æ€§ä¹³è…ºç™Œ (female breast carcinoma)** æœ‰æ•ˆï¼Œ
ç›®å‰æœ‰è¶…é **50 å€‹è‡¨åºŠè©¦é©—**æ”¯æŒé€™å€‹æ–¹å‘ã€‚
</p>

## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | HER2 é™½æ€§æ—©æœŸä¹³ç™Œã€è½‰ç§»æ€§ä¹³ç™Œã€é»‘è‰²ç´ ç˜¤ã€éå°ç´°èƒè‚ºç™Œã€ä½•æ°é‡‘æ°æ·‹å·´ç˜¤ã€é ­é ¸éƒ¨é±—ç‹€ç´°èƒç™Œã€æ³Œå°¿é“ä¸Šçš®ç™Œç­‰ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | å¥³æ€§ä¹³è…ºç™Œã€primary non-gestational choriocarcinoma of ovaryã€hereditary breast ovarian cancer syndromeã€ovarian clear cell adenocarcinomaã€ovarian mucinous adenocarcinomaã€yolk sac tumorã€maligant granulosa cell tumor of ovaryã€ovarian endometrioid adenocarcinomaã€rectum mucinous adenocarcinomaã€colon mucinous adenocarcinoma |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.86% |
| è­‰æ“šç­‰ç´š | L2 |
| å°ç£ä¸Šå¸‚ | å·²ä¸Šå¸‚ï¼ˆç‚ºå¤šç¨®è¤‡æ–¹æ²»ç™‚çš„ä¸€éƒ¨åˆ†ï¼‰ |
| è¨±å¯è­‰æ•¸ | å¤šå¼µï¼ˆä½œç‚º Trastuzumabã€Pembrolizumab ç­‰è—¥ç‰©é©æ‡‰ç—‡çš„ä½µç”¨è—¥ç‰©ï¼‰ |
| å»ºè­°æ±ºç­– | Proceed with Guardrails |





## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. female breast carcinoma</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.86%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content">

<h3>ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ</h3>

<p>Carboplatin æ˜¯ä¸€ç¨®é‰‘é¡æŠ—ç™Œè—¥ç‰©ï¼Œé€éèˆ‡ DNA å½¢æˆäº¤å‰é€£çµä¾†æŠ‘åˆ¶è…«ç˜¤ç´°èƒå¢æ®–ã€‚å…¶ä½œç”¨æ©Ÿè½‰åŒ…æ‹¬ï¼š</p>

<ol>
<li><strong>DNA æå‚·æ©Ÿåˆ¶</strong>ï¼šCarboplatin èˆ‡ DNA å½¢æˆé‰‘-DNA åŠ åˆç‰©ï¼Œå¹²æ“¾ DNA è¤‡è£½èˆ‡è½‰éŒ„</li>
<li><strong>ç´°èƒé€±æœŸé˜»æ»¯</strong>ï¼šèª˜å°ç´°èƒé€±æœŸåœæ»¯ï¼Œä¿ƒé€²è…«ç˜¤ç´°èƒå‡‹äº¡</li>
<li><strong>å°ä¸‰é™°æ€§ä¹³è…ºç™Œçš„ç‰¹æ®Šç™‚æ•ˆ</strong>ï¼šç ”ç©¶é¡¯ç¤º carboplatin å° BRCA çªè®Šç›¸é—œçš„ä¸‰é™°æ€§ä¹³è…ºç™Œå…·æœ‰è‰¯å¥½ç™‚æ•ˆ</li>
</ol>

<h3>è‡¨åºŠè©¦é©—</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06636591" target="_blank">NCT06636591</a></td><td>NA</td><td>RECRUITING</td><td>14</td><td>A Prospective, Open-label, Single-center, Pilot Study of Neoadjuvant Chemotherap...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06027268" target="_blank">NCT06027268</a></td><td>PHASE2</td><td>ACTIVE_NOT_RECRUITING</td><td>36</td><td>ToPCourT: A Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carbop...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01104935" target="_blank">NCT01104935</a></td><td>PHASE3</td><td>COMPLETED</td><td>275</td><td>Evaluation of Trastuzumab Without Chemotherapy as a Postoperative Adjuvant Thera...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05809895" target="_blank">NCT05809895</a></td><td>PHASE2</td><td>WITHDRAWN</td><td>0</td><td>AdvanTIG-211: A Randomized, Double-blind, Placebo-controlled, Phase II Study Eva...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00589238" target="_blank">NCT00589238</a></td><td>PHASE2</td><td>TERMINATED</td><td>16</td><td>Randomised Phase II Trial of Neoadjuvant Weekly Paclitaxel Plus Carboplatin Comp...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00669747" target="_blank">NCT00669747</a></td><td>PHASE2</td><td>UNKNOWN</td><td>45</td><td>A Phase II Randomized Study Of Intraductal Carboplatin In Women With Ductal Carc...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03799679" target="_blank">NCT03799679</a></td><td>PHASE4</td><td>UNKNOWN</td><td>60</td><td>Nanoparticle Albumin-Bound Paclitaxel Followed by Dose-Intensive Epirubicin in C...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03644342" target="_blank">NCT03644342</a></td><td>PHASE1, PHASE2</td><td>TERMINATED</td><td>4</td><td>Phase I/II Study of Niraparib With Radiotherapy for Treatment of Metastatic Inva...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05867251" target="_blank">NCT05867251</a></td><td>PHASE1, PHASE2</td><td>RECRUITING</td><td>430</td><td>A Phase 1/2, First-in-Human Study to Assess the Safety, Tolerability, Pharmacoki...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01881230" target="_blank">NCT01881230</a></td><td>PHASE2, PHASE3</td><td>COMPLETED</td><td>191</td><td>A Phase 2/3, Multi-Center, Open-Label, Randomized Study of Weekly NabÂ®-Paclitaxe...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00047255" target="_blank">NCT00047255</a></td><td>PHASE3</td><td>COMPLETED</td><td>263</td><td>A Multicenter Phase III Randomized Trial Comparing Docetaxel (Taxotere) and Tras...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04975451" target="_blank">NCT04975451</a></td><td>PHASE2</td><td>UNKNOWN</td><td>30</td><td>Neoadjuvant Treatment Anlotinib Combined With Docetaxel and Carboplatin in Tripl...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03717415" target="_blank">NCT03717415</a></td><td>PHASE1, PHASE2</td><td>TERMINATED</td><td>70</td><td>An Open Label, Multicenter, Phase 1b/2 Study of Rebastinib (DCC-2036) in Combina...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06234137" target="_blank">NCT06234137</a></td><td>NA</td><td>RECRUITING</td><td>154</td><td>A Prospective, Open, Multicenter Single-arm Clinical Studie of Docetaxel, Carbop...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01445418" target="_blank">NCT01445418</a></td><td>PHASE1</td><td>COMPLETED</td><td>103</td><td>A Phase I Study With an Expansion Cohort of the PARP Inhibitor AZD2281 (KU-00594...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04644068" target="_blank">NCT04644068</a></td><td>PHASE1, PHASE2</td><td>ACTIVE_NOT_RECRUITING</td><td>702</td><td>A Modular Phase I/IIa, Open-label, Multicentre Study to Assess the Safety, Toler...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00954174" target="_blank">NCT00954174</a></td><td>PHASE3</td><td>UNKNOWN</td><td>637</td><td>A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Pl...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03134638" target="_blank">NCT03134638</a></td><td>PHASE1</td><td>TERMINATED</td><td>107</td><td>A Phase 1 Study of SY-1365, a Selective CDK7 Inhibitor, in Adult Patients With A...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT07074106" target="_blank">NCT07074106</a></td><td>PHASE2</td><td>NOT_YET_RECRUITING</td><td>40</td><td>DespaTIL Study: A Phase II Trial of De-escalated Neoadjuvant Chemotherapy for Ea...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT07103447" target="_blank">NCT07103447</a></td><td>PHASE2</td><td>NOT_YET_RECRUITING</td><td>54</td><td>A Prospective, Multicenter, Single-Arm Study of AK112 in Combination With Albumi...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00262847" target="_blank">NCT00262847</a></td><td>PHASE3</td><td>COMPLETED</td><td>1873</td><td>A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04677816" target="_blank">NCT04677816</a></td><td>PHASE2</td><td>RECRUITING</td><td>50</td><td>Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01405924" target="_blank">NCT01405924</a></td><td>PHASE2</td><td>TERMINATED</td><td>111</td><td>EMENDÂ® IV In Salvage Treatment of Chemotherapy-Induced Vomiting</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02993094" target="_blank">NCT02993094</a></td><td>PHASE1, PHASE2</td><td>TERMINATED</td><td>31</td><td>Ixazomib (MLN9708) in Combination With Carboplatin in Pretreated Women With Adva...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00006123" target="_blank">NCT00006123</a></td><td>PHASE1, PHASE2</td><td>WITHDRAWN</td><td>0</td><td>Autotransplantation and Her 2 Neu Antibody Immunotherapy in Advanced Breast Canc...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02046421" target="_blank">NCT02046421</a></td><td>PHASE1</td><td>COMPLETED</td><td>31</td><td>Carboplatin, Gemcitabine, and Mifepristone for Advanced Breast Cancer and Recurr...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02003209" target="_blank">NCT02003209</a></td><td>PHASE3</td><td>COMPLETED</td><td>315</td><td>A Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Pa...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00769470" target="_blank">NCT00769470</a></td><td>PHASE2</td><td>COMPLETED</td><td>18</td><td>A Multicenter, Open Label, Randomized Phase II Trial of Presurgical Treatment Wi...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00254592" target="_blank">NCT00254592</a></td><td>PHASE2</td><td>COMPLETED</td><td>43</td><td>Neoadjuvant Biweekly Doxorubicin and Cyclophosphamide With GMCSF Followed by Wee...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00232505" target="_blank">NCT00232505</a></td><td>PHASE2</td><td>COMPLETED</td><td>112</td><td>Phase II Trial of Cetuximab Alone and in Combination With Carboplatin in ER-Nega...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00535119" target="_blank">NCT00535119</a></td><td>PHASE1</td><td>COMPLETED</td><td>107</td><td>A Phase 1 Study of ABT-888 in Combination With Carboplatin and Paclitaxel in Adv...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00002628" target="_blank">NCT00002628</a></td><td>PHASE1, PHASE2</td><td>UNKNOWN</td><td>50</td><td>PHASE I/II TRIAL OF THE ADDITION OF TAXOL TO THE HIGH DOSE CARBOPLATIN AND CYCLO...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00002780" target="_blank">NCT00002780</a></td><td>PHASE1, PHASE2</td><td>UNKNOWN</td><td>60</td><td>INFUSION OF ACTIVATED T CELLS AND LOW DOSE INTERLEUKIN 2 COMBINED WITH PERIPHERA...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02413320" target="_blank">NCT02413320</a></td><td>PHASE2</td><td>COMPLETED</td><td>101</td><td>Randomized Open Label Phase II Trial of Neoadjuvant Carboplatin Plus Docetaxel o...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00002772" target="_blank">NCT00002772</a></td><td>PHASE3</td><td>TERMINATED</td><td>602</td><td>A Comparison of Intensive Sequential Chemotherapy Using Doxorubicin Plus Paclita...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00118053" target="_blank">NCT00118053</a></td><td>PHASE2</td><td>TERMINATED</td><td>5</td><td>A Phase II Trial of Taxotere, Carboplatin and Herceptin in Locally Advanced or I...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04095364" target="_blank">NCT04095364</a></td><td>PHASE3</td><td>ACTIVE_NOT_RECRUITING</td><td>450</td><td>A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letr...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01167712" target="_blank">NCT01167712</a></td><td>PHASE3</td><td>ACTIVE_NOT_RECRUITING</td><td>692</td><td>GOG-0262: A Phase III Trial of Every-3-Weeks Paclitaxel Versus Dose Dense Weekly...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02102438" target="_blank">NCT02102438</a></td><td>NA</td><td>WITHDRAWN</td><td>0</td><td>Neoadjuvant or Adjuvant Chemotherapy Without Anthracyclines for Elderly Patients...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00565851" target="_blank">NCT00565851</a></td><td>PHASE3</td><td>ACTIVE_NOT_RECRUITING</td><td>1052</td><td>A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00005798" target="_blank">NCT00005798</a></td><td>PHASE2</td><td>COMPLETED</td><td>209</td><td>A Phase II Study of Cyclophosphamide, Thiotepa, and Carboplatin (CTC) as a Prepa...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05843292" target="_blank">NCT05843292</a></td><td>PHASE4</td><td>NOT_YET_RECRUITING</td><td>48</td><td>Short-term Sintilimab in Combination With Taxane and Carboplatin for Neoadjuvant...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04771871" target="_blank">NCT04771871</a></td><td>PHASE2</td><td>UNKNOWN</td><td>42</td><td>Treatment Response and microRNA Profiles in Triple Negative Breast Cancer Patien...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03678883" target="_blank">NCT03678883</a></td><td>PHASE2</td><td>ACTIVE_NOT_RECRUITING</td><td>350</td><td>Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3Î²) Inhibito...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02418624" target="_blank">NCT02418624</a></td><td>PHASE1</td><td>COMPLETED</td><td>25</td><td>A Phase I Followed by a Randomized Phase II Trial of Two Cycles Carboplatin-Olap...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06047379" target="_blank">NCT06047379</a></td><td>PHASE1, PHASE2</td><td>RECRUITING</td><td>134</td><td>An Open-label Phase 1/2 Dose Finding, Safety and Efficacy Study of Oral NEO212 i...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02124902" target="_blank">NCT02124902</a></td><td>PHASE2</td><td>TERMINATED</td><td>148</td><td>A Co-clinical Trial in Triple Negative Breast Cancer Patients With Genoproteomic...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06139107" target="_blank">NCT06139107</a></td><td>PHASE1</td><td>RECRUITING</td><td>15</td><td>RADIANT Study: Pre-op Radiation With Abemaciclib Andletrozole in Early Stage Bre...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00532727" target="_blank">NCT00532727</a></td><td>PHASE3</td><td>UNKNOWN</td><td>400</td><td>Triple Negative Trial: A Randomised Phase III Trial of Carboplatin Compared to D...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01237067" target="_blank">NCT01237067</a></td><td>PHASE1</td><td>COMPLETED</td><td>77</td><td>A Pharmacokinetic/Pharmacodynamic Study With a Phase I Run-In With a PARP Inhibi...</td></tr>
</tbody>
</table>

<h3>ç›¸é—œæ–‡ç»</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33208340/" target="_blank">33208340</a></td><td>2021</td><td>Article</td><td>Clinical cancer research : an </td><td>Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neo...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39671272/" target="_blank">39671272</a></td><td>2025</td><td>Article</td><td>JAMA</td><td>Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatmen...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/40593759/" target="_blank">40593759</a></td><td>2025</td><td>Article</td><td>Nature communications</td><td>Neoadjuvant ARX788 plus pyrotinib versus trastuzumab, pertuzumab, docetaxel and ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/8893899/" target="_blank">8893899</a></td><td>1996</td><td>Article</td><td>Seminars in oncology</td><td>Paclitaxel and carboplatin for advanced breast cancer.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/40779028/" target="_blank">40779028</a></td><td>2025</td><td>Article</td><td>Breast cancer research and tre</td><td>Carboplatin, gemcitabine, and mifepristone for advanced breast and recurrent/per...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33256829/" target="_blank">33256829</a></td><td>2020</td><td>Article</td><td>Breast cancer research : BCR</td><td>Phase II trial of carboplatin and bevacizumab in patients with breast cancer bra...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/25247558/" target="_blank">25247558</a></td><td>2014</td><td>Article</td><td>PloS one</td><td>Both carboplatin and bevacizumab improve pathological complete remission rate in...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39558836/" target="_blank">39558836</a></td><td>2024</td><td>Article</td><td>Drug development research</td><td>Formulation and Characterization of RBCS Coated Carboplatin Loaded Nano-Liposoma...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/16720915/" target="_blank">16720915</a></td><td>2006</td><td>Article</td><td>Medical oncology (Northwood, L</td><td>Paclitaxel-carboplatin combination chemotherapy in advanced breast cancer: accum...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28126294/" target="_blank">28126294</a></td><td>2017</td><td>Article</td><td>International journal of radia</td><td>Internal Mammary Misfortune.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28040858/" target="_blank">28040858</a></td><td>2017</td><td>Article</td><td>Breast cancer research and tre</td><td>Multicenter analysis of neoadjuvant docetaxel, carboplatin, and trastuzumab in H...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/35462344/" target="_blank">35462344</a></td><td>2022</td><td>Article</td><td>Breast (Edinburgh, Scotland)</td><td>Moment of truth-adding carboplatin to neoadjuvant/adjuvant chemotherapy in tripl...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39039516/" target="_blank">39039516</a></td><td>2024</td><td>Article</td><td>BMC cancer</td><td>Neoadjuvant inetetamab and pertuzumab with taxanes and carboplatin (TCbIP) In lo...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38309017/" target="_blank">38309017</a></td><td>2024</td><td>Article</td><td>European journal of cancer (Ox</td><td>Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/22350024/" target="_blank">22350024</a></td><td>2013</td><td>Article</td><td>International journal of clini</td><td>Gemcitabine and carboplatin for pretreated metastatic breast cancer: the predict...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/35837812/" target="_blank">35837812</a></td><td>2023</td><td>Article</td><td>Cancer medicine</td><td>Anaemia and pathologic complete response rate according to carboplatin dose in H...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/23682812/" target="_blank">23682812</a></td><td>2013</td><td>Article</td><td>The breast journal</td><td>Paclitaxel, carboplatin, and trastuzumab in a neo-adjuvant regimen for HER2-posi...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/40706743/" target="_blank">40706743</a></td><td>2025</td><td>Article</td><td>Cancer letters</td><td>Dual regulation of FZD1/7 by IGF2BP3 enhances stem-like properties and carboplat...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36270425/" target="_blank">36270425</a></td><td>2022</td><td>Article</td><td>Life sciences</td><td>Inhibition of thioredoxin reductase 1 by vulpinic acid suppresses the proliferat...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/29153775/" target="_blank">29153775</a></td><td>2018</td><td>Article</td><td>Clinical breast cancer</td><td>Weekly Paclitaxel and Carboplatin Plus Bevacizumab as First-Line Treatment of Me...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. rectum mucinous adenocarcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.28%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. colon mucinous adenocarcinoma</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.26%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ7 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/21794003/" target="_blank">21794003</a></td><td>2011</td><td>Article</td><td>The journal of obstetrics and </td><td>Metastatic urachal carcinoma of the ovary.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33298341/" target="_blank">33298341</a></td><td>2021</td><td>Article</td><td>European journal of surgical o</td><td>Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/15852675/" target="_blank">15852675</a></td><td>2005</td><td>Article</td><td>Hinyokika kiyo. Acta urologica</td><td>[Carcinoma of the urachus: a case report].</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/29927186/" target="_blank">29927186</a></td><td>2016</td><td>Article</td><td>Journal of the Medical Associa</td><td>Co-Existing Ovarian Mucinous Cystadenocarcinoma with Mature Cystic Teratoma: A R...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/11420638/" target="_blank">11420638</a></td><td>2001</td><td>Article</td><td>Gene therapy</td><td>Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/17357215/" target="_blank">17357215</a></td><td>2005</td><td>Article</td><td>Journal of B.U.ON. : official </td><td>Carcinoma of sigmoid colon after ureterosigmoidostomy.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/16957443/" target="_blank">16957443</a></td><td>2006</td><td>Article</td><td>Skinmed</td><td>Sister Mary Joseph&#x27;s nodule as a presenting sign of internal malignancy.</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. adult germ cell tumor</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.24%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ50 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01445119" target="_blank">NCT01445119</a></td><td>PHASE1</td><td>COMPLETED</td><td>58</td><td>A Phase I Trial of Enzastaurin (LY317615) in Combination With Carboplatin in Adu...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00293358" target="_blank">NCT00293358</a></td><td>PHASE3</td><td>COMPLETED</td><td>500</td><td>SIOP Intracranial Germ Cell Tumours Protocol</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00010036" target="_blank">NCT00010036</a></td><td>PHASE2</td><td>COMPLETED</td><td>N/A</td><td>A Phase I/II Trial of CPT-11 With Carboplatin in Patients With Glioblastoma Mult...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00536601" target="_blank">NCT00536601</a></td><td>NA</td><td>COMPLETED</td><td>174</td><td>Autologous Blood and Marrow Transplantation for Hematologic Malignancies and Sel...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01857453" target="_blank">NCT01857453</a></td><td>PHASE2</td><td>UNKNOWN</td><td>97</td><td>National, Multicentric, Prospective Phase II Study Estimating the Interest of a ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05180825" target="_blank">NCT05180825</a></td><td>PHASE2</td><td>RECRUITING</td><td>134</td><td>A Randomized and Controlled Phase II Protocol in Non NF1 Pediatric and AYA (Adol...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03744026" target="_blank">NCT03744026</a></td><td>PHASE1, PHASE2</td><td>COMPLETED</td><td>38</td><td>A Study to Evaluate the Safety and the Efficacy of Transient Opening of the Bloo...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00005976" target="_blank">NCT00005976</a></td><td>PHASE2</td><td>COMPLETED</td><td>60</td><td>Phase I/II Trial of Pyrazoloacridine and Carboplatin in Patients With Recurrent ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01172912" target="_blank">NCT01172912</a></td><td>PHASE2</td><td>UNKNOWN</td><td>47</td><td>Tandem High-Dose Chemotherapy (HDCT) With Peripheral-Blood Stem-Cell Rescue for ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00432094" target="_blank">NCT00432094</a></td><td>PHASE2</td><td>COMPLETED</td><td>23</td><td>Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01295944" target="_blank">NCT01295944</a></td><td>PHASE2</td><td>COMPLETED</td><td>35</td><td>Phase II Trial of Carboplatin and Bevacizumab for the Treatment of Recurrent Low...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00187109" target="_blank">NCT00187109</a></td><td>PHASE1, PHASE2</td><td>COMPLETED</td><td>40</td><td>A Phase I/II Trial of Recombinant Human Thrombopoietin in Children With Malignan...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00003657" target="_blank">NCT00003657</a></td><td>PHASE2</td><td>COMPLETED</td><td>24</td><td>High Dose Ifosfamide, Carboplatin and Etoposide With Amifostine Chemoprotection</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03678883" target="_blank">NCT03678883</a></td><td>PHASE2</td><td>ACTIVE_NOT_RECRUITING</td><td>350</td><td>Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3Î²) Inhibito...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00003690" target="_blank">NCT00003690</a></td><td>PHASE1</td><td>COMPLETED</td><td>48</td><td>Phase I Study of Flavopiridol in Combination With Cisplatin in Patients With Adv...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00336024" target="_blank">NCT00336024</a></td><td>PHASE3</td><td>COMPLETED</td><td>91</td><td>A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06047379" target="_blank">NCT06047379</a></td><td>PHASE1, PHASE2</td><td>RECRUITING</td><td>134</td><td>An Open-label Phase 1/2 Dose Finding, Safety and Efficacy Study of Oral NEO212 i...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00021307" target="_blank">NCT00021307</a></td><td>PHASE1, PHASE2</td><td>WITHDRAWN</td><td>0</td><td>Phase I/II Trial Of Temozolomide And Carboplatin In Recurrent Glioblastoma Multi...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04684368" target="_blank">NCT04684368</a></td><td>PHASE2</td><td>RECRUITING</td><td>160</td><td>A Phase 2 Trial of Chemotherapy Followed by Response-Based Whole Ventricular &amp;Am...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00002931" target="_blank">NCT00002931</a></td><td>PHASE2</td><td>COMPLETED</td><td>48</td><td>Tandem High-Dose Chemotherapy With Autologous Stem Cell Rescue for Poor-Prognosi...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00541138" target="_blank">NCT00541138</a></td><td>PHASE2</td><td>COMPLETED</td><td>50</td><td>A Pilot Study of Tamoxifen, Carboplatin and Topotecan in the Treatment of Recurr...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05705687" target="_blank">NCT05705687</a></td><td>NA</td><td>RECRUITING</td><td>150</td><td>A Prospective Program Aiming at Improving Outcome for Young Adults With Poor-pro...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03067181" target="_blank">NCT03067181</a></td><td>PHASE3</td><td>RECRUITING</td><td>1780</td><td>A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Ca...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01966913" target="_blank">NCT01966913</a></td><td>PHASE1, PHASE2</td><td>UNKNOWN</td><td>30</td><td>Salvage Chemotherapy for Poor Prognosis Germ Cell Tumors - A Phase I-II Sequenti...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00007813" target="_blank">NCT00007813</a></td><td>PHASE1</td><td>COMPLETED</td><td>21</td><td>TREATMENT OF CHILDREN AND YOUNG ADULTS WITH RECURRENT/REFRACTORY SOLID TUMORS WI...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00014105" target="_blank">NCT00014105</a></td><td>PHASE1, PHASE2</td><td>UNKNOWN</td><td>N/A</td><td>Phase I/II Trial of Temozolomide and Carboplatin in Recurrent Glioblastoma Multi...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04198766" target="_blank">NCT04198766</a></td><td>PHASE1, PHASE2</td><td>ACTIVE_NOT_RECRUITING</td><td>296</td><td>An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Multicohort, Phase ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00006263" target="_blank">NCT00006263</a></td><td>PHASE2</td><td>WITHDRAWN</td><td>0</td><td>Phase II Trial of Temozolomide, Carboplatin and Neupogen in High-Grade Gliomas, ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05599984" target="_blank">NCT05599984</a></td><td>PHASE1</td><td>ACTIVE_NOT_RECRUITING</td><td>288</td><td>A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01424839" target="_blank">NCT01424839</a></td><td>PHASE4</td><td>UNKNOWN</td><td>400</td><td>SIOP CNS GCT II: Prospective Trial for the Diagnosis and Treatment of Children, ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00021047" target="_blank">NCT00021047</a></td><td>PHASE1, PHASE2</td><td>COMPLETED</td><td>N/A</td><td>A Phase I/II Trial of Epirubicin, Carboplatin &amp; Capecitabine in Adult Cancer Pat...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00008086" target="_blank">NCT00008086</a></td><td>PHASE1</td><td>COMPLETED</td><td>N/A</td><td>A Phase I Trial of Subcutaneous And/Or Oral Calcitriol [(1,25-COH)2D3] and Carbo...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03149575" target="_blank">NCT03149575</a></td><td>PHASE3</td><td>TERMINATED</td><td>2</td><td>A Pivotal Randomized, Controlled Trial of VAL-083 in Patients With Recurrent Gli...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00492687" target="_blank">NCT00492687</a></td><td>PHASE2</td><td>UNKNOWN</td><td>80</td><td>A Phase II Pilot Trial of Radiation Therapy With Concurrent and Adjuvant Temozol...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01248949" target="_blank">NCT01248949</a></td><td>PHASE1</td><td>COMPLETED</td><td>162</td><td>Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safe...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06333314" target="_blank">NCT06333314</a></td><td>PHASE2</td><td>RECRUITING</td><td>120</td><td>Dostarlimab as First-line Treatment for Patients With dMMR/MSI (Non-colorectal/N...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00995007" target="_blank">NCT00995007</a></td><td>PHASE2</td><td>COMPLETED</td><td>112</td><td>A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplat...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00002749" target="_blank">NCT00002749</a></td><td>PHASE2</td><td>COMPLETED</td><td>25</td><td>PHASE II STUDY OF CARBOPLATIN (CBDCA) IN THE TREATMENT OF CHILDREN AND ADULTS WI...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01386710" target="_blank">NCT01386710</a></td><td>PHASE1, PHASE2</td><td>SUSPENDED</td><td>54</td><td>Phase I/II Trial Of Repeated Super-selective Intraarterial Cerebral Infusion Of ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00423852" target="_blank">NCT00423852</a></td><td>PHASE1, PHASE2</td><td>COMPLETED</td><td>26</td><td>Phase I/II Trial of Sequential Paclitaxel/Ifosfamide Followed by Dose-Escalated,...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00002854" target="_blank">NCT00002854</a></td><td>PHASE1</td><td>COMPLETED</td><td>33</td><td>PHASE I PILOT STUDY OF SEQUENTIAL HIGH DOSE CYCLES OF CISPLATIN, CYCLOPHOSPHAMID...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00555399" target="_blank">NCT00555399</a></td><td>PHASE1, PHASE2</td><td>TERMINATED</td><td>55</td><td>Phase I / II Adaptive Randomized Trial of Vorinostat, Isotretinoin and Temozolom...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01317212" target="_blank">NCT01317212</a></td><td>PHASE1</td><td>WITHDRAWN</td><td>0</td><td>A Phase I Trial of Carboplatin Administered by Convection-Enhanced Delivery to P...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06368817" target="_blank">NCT06368817</a></td><td>PHASE2</td><td>RECRUITING</td><td>240</td><td>A Phase II Trial Evaluating Chemotherapy Followed by Response-Based Reduced Radi...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01644955" target="_blank">NCT01644955</a></td><td>PHASE1</td><td>COMPLETED</td><td>10</td><td>Intracerebral Convection Enhanced Delivery of Carboplatin for Treatment of Recur...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00058071" target="_blank">NCT00058071</a></td><td>PHASE3</td><td>COMPLETED</td><td>100</td><td>A Randomized Phase III Trial of Amifostine vs. No Treatment for Platinum Induced...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02820857" target="_blank">NCT02820857</a></td><td>PHASE2</td><td>COMPLETED</td><td>153</td><td>Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00352313" target="_blank">NCT00352313</a></td><td>PHASE1, PHASE2</td><td>COMPLETED</td><td>82</td><td>A Phase I/II Study of ATN-161 and Carboplatin in Adult Patients With Recurrent I...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02341456" target="_blank">NCT02341456</a></td><td>PHASE1</td><td>COMPLETED</td><td>19</td><td>A Phase Ib, Dose Finding Study Evaluating AZD1775 in Monotherapy, in Combination...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00408655" target="_blank">NCT00408655</a></td><td>PHASE1</td><td>COMPLETED</td><td>38</td><td>Phase I Study of CCI-779 (NSC 683864) in Combination With Carboplatin and Paclit...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. cervical mucinous adenocarcinoma</span>
<span class="evidence-badge evidence-L2">L2</span>
<span class="prediction-score">99.24%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ2 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01652794" target="_blank">NCT01652794</a></td><td>PHASE1</td><td>COMPLETED</td><td>12</td><td>A Phase 1 Study of Carboplatin and Gemcitabine Chemotherapy and Stereotactic Bod...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06870565" target="_blank">NCT06870565</a></td><td>PHASE3</td><td>NOT_YET_RECRUITING</td><td>238</td><td>A Multicenter Randomized Study Comparing Paclitaxel and Platinum-based Concurren...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. gallbladder mucinous adenocarcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.23%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. endometrial mucinous adenocarcinoma</span>
<span class="evidence-badge evidence-L2">L2</span>
<span class="prediction-score">99.20%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ3 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01652794" target="_blank">NCT01652794</a></td><td>PHASE1</td><td>COMPLETED</td><td>12</td><td>A Phase 1 Study of Carboplatin and Gemcitabine Chemotherapy and Stereotactic Bod...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01081262" target="_blank">NCT01081262</a></td><td>PHASE3</td><td>ACTIVE_NOT_RECRUITING</td><td>50</td><td>A GCIG Intergroup Multicenter Phase III Trial of Open Label Carboplatin and Pacl...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01440998" target="_blank">NCT01440998</a></td><td>PHASE1</td><td>COMPLETED</td><td>18</td><td>Pilot and Translational Study of Dasatinib (NSC#732517) Paclitaxel and Carboplat...</td></tr>
</tbody>
</table>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ20 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34092768/" target="_blank">34092768</a></td><td>2021</td><td>Article</td><td>Journal of UOEH</td><td>Synchronous Occurrence of Ovarian Seromucinous Carcinoma and Endometrial Mucinou...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/19473054/" target="_blank">19473054</a></td><td>2009</td><td>Article</td><td>Neoplasma</td><td>Gemcitabine and carboplatin treatment in patients with relapsing ovarian cancer.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30718314/" target="_blank">30718314</a></td><td>2019</td><td>Article</td><td>International journal of gynec</td><td>Adenosine triphosphate-based chemotherapy response assay predicts long-term surv...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/16884360/" target="_blank">16884360</a></td><td>2006</td><td>Article</td><td>International journal of gynec</td><td>Interferon-gamma in combination with carboplatin and paclitaxel as a safe and ef...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/26763061/" target="_blank">26763061</a></td><td>2015</td><td>Article</td><td>Annals of the Academy of Medic</td><td>Singapore Cancer Network (SCAN) Guidelines for the Systemic Therapy of Endometri...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30448882/" target="_blank">30448882</a></td><td>2019</td><td>Article</td><td>Journal of cancer research and</td><td>Calpain system protein expression and activity in ovarian cancer.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/26514517/" target="_blank">26514517</a></td><td>2015</td><td>Article</td><td>Asian Pacific journal of cance</td><td>Treatment Outcomes of Epithelial Ovarian Cancers Following Maximum Cytoreduction...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/26216383/" target="_blank">26216383</a></td><td>2015</td><td>Article</td><td>Annals of oncology : official </td><td>A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/27172750/" target="_blank">27172750</a></td><td>2016</td><td>Article</td><td>European journal of gynaecolog</td><td>Stage IVB endometrial cancer confined to the abdomen: is chemotherapy superior t...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/32711417/" target="_blank">32711417</a></td><td>2020</td><td>Article</td><td>Asian Pacific journal of cance</td><td>ERCC1, XRCC1, and GSTP1 Polymorphisms and Treatment Outcomes of Advanced Epithel...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30030657/" target="_blank">30030657</a></td><td>2019</td><td>Article</td><td>International journal of clini</td><td>Bevacizumab combined with platinum-taxane chemotherapy as first-line treatment f...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/26825824/" target="_blank">26825824</a></td><td>2016</td><td>Article</td><td>International journal of gynec</td><td>Continuous Low-Dose Oral Cyclophosphamide and Methotrexate as Maintenance Therap...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/29117336/" target="_blank">29117336</a></td><td>2017</td><td>Article</td><td>Annals of oncology : official </td><td>Clinical and genetic predictors of paclitaxel neurotoxicity based on patient- ve...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/26237194/" target="_blank">26237194</a></td><td>2017</td><td>Article</td><td>American journal of clinical o</td><td>Survival Outcomes Improved in Contemporary Cohort of Patients With Pelvic or Abd...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/18465140/" target="_blank">18465140</a></td><td>2008</td><td>Article</td><td>Journal of cancer research and</td><td>Novel treatment of ovarian cancer cell lines with Imatinib mesylate combined wit...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/24147606/" target="_blank">24147606</a></td><td>2014</td><td>Article</td><td>The journal of obstetrics and </td><td>Triple simultaneous primary invasive gynecological malignancies: a case report.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/21229624/" target="_blank">21229624</a></td><td>2010</td><td>Article</td><td>Journal of B.U.ON. : official </td><td>Adjuvant platinum-based chemotherapy in patients with epithelial ovarian cancer:...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/19574766/" target="_blank">19574766</a></td><td>2009</td><td>Article</td><td>International journal of gynec</td><td>The relationship of platinum resistance and ERCC1 protein expression in epitheli...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/24662134/" target="_blank">24662134</a></td><td>2014</td><td>Article</td><td>International journal of gynec</td><td>Survivin expression as a prognostic factor in patients with epithelial ovarian c...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/21430456/" target="_blank">21430456</a></td><td>2011</td><td>Article</td><td>International journal of gynec</td><td>Consistency of in vitro chemoresponse assay results and population clinical resp...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. endometrial mixed adenocarcinoma</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.20%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ4 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05252416" target="_blank">NCT05252416</a></td><td>PHASE1</td><td>TERMINATED</td><td>50</td><td>A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03914612" target="_blank">NCT03914612</a></td><td>PHASE3</td><td>ACTIVE_NOT_RECRUITING</td><td>813</td><td>A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05542407" target="_blank">NCT05542407</a></td><td>PHASE1</td><td>RECRUITING</td><td>58</td><td>Phase 1 Clinical Trial of ONC201 and Atezolizumab in Obesity-Driven Endometrial ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05256225" target="_blank">NCT05256225</a></td><td>PHASE3</td><td>RECRUITING</td><td>360</td><td>A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Tra...</td></tr>
</tbody>
</table>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ10 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/25611899/" target="_blank">25611899</a></td><td>2015</td><td>Article</td><td>International journal of gynec</td><td>Carboplatin and nonpegylated liposomal doxorubicin in primary advanced or recurr...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/19890461/" target="_blank">19890461</a></td><td>2006</td><td>Article</td><td>American journal of pharmacolo</td><td>Sensitivities of Uterine Adenocarcinoma, Mixed Mullerian Tumor (MMT) and Sarcoma...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/10811505/" target="_blank">10811505</a></td><td>2000</td><td>Article</td><td>Annals of oncology : official </td><td>Endometrial mesodermal mixed tumor occurring after tamoxifen treatment: report o...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31993743/" target="_blank">31993743</a></td><td>2020</td><td>Article</td><td>Journal of cancer research and</td><td>Should MMMT still be treated with adjuvant taxane-based combination chemotherapy...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/14599858/" target="_blank">14599858</a></td><td>2003</td><td>Article</td><td>Gynecologic oncology</td><td>A phase II trial of three sequential doublets for the treatment of advanced mÃ¼ll...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/41079099/" target="_blank">41079099</a></td><td>2025</td><td>Article</td><td>Frontiers in oncology</td><td>A endometrial malignant tumor with yolk sac tumor component: a case report and l...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/18096209/" target="_blank">18096209</a></td><td>2008</td><td>Article</td><td>Gynecologic oncology</td><td>Outcome after combined modality treatment for uterine papillary serous carcinoma...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/24772925/" target="_blank">24772925</a></td><td>2014</td><td>Article</td><td>European journal of gynaecolog</td><td>Malignant mixed MÃ¼llerian tumor with small cell neuroendocrine differentiation: ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/22619932/" target="_blank">22619932</a></td><td>2011</td><td>Article</td><td>Journal of the Medical Associa</td><td>Failed conservative treatment of synchronous primary cancer of endometrium and o...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/15300428/" target="_blank">15300428</a></td><td>2004</td><td>Article</td><td>Journal of cancer research and</td><td>Chemotherapeutic management of recurrent/metastatic uterine carcinosarcomas (mal...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. villoglandular endometrial endometrioid adenocarcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.20%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. extrahepatic bile duct mucinous adenocarcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.18%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ |
|---------|------|------|-----------|
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬027591è™Ÿ | æ›²æ–¯è‹¥å‡æ™¶æ³¨å°„åŠ‘150æ¯«å…‹ | å‡æ™¶æ³¨å°„åŠ‘ | èˆ‡ docetaxel åŠ carboplatin ä½µç”¨ä¹‹ HER2 é™½æ€§æ—©æœŸä¹³ç™Œè¼”åŠ©ç™‚æ³• |
| è¡›ç½²è—¥è¼¸å­—ç¬¬027591è™Ÿ | è³€ç™Œå¹³çš®ä¸‹æ³¨å°„åŠ‘ | çš®ä¸‹æ³¨å°„åŠ‘ | èˆ‡ docetaxel åŠ carboplatin ä½µç”¨ä¹‹ HER2 é™½æ€§æ—©æœŸä¹³ç™Œè¼”åŠ©ç™‚æ³• |
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬028264è™Ÿ | å‰èˆ’é”è†œè¡£éŒ  | è†œè¡£éŒ  | èˆ‡ pemetrexed åŠ carboplatin ä½µç”¨ä¹‹è½‰ç§»æ€§éé±—ç‹€éå°ç´°èƒè‚ºç™Œç¬¬ä¸€ç·šæ²»ç™‚ |

## ç´°èƒæ¯’æ€§

| é …ç›® | å…§å®¹ |
|------|------|
| ç´°èƒæ¯’æ€§åˆ†é¡ | å‚³çµ±ç´°èƒæ¯’æ€§è—¥ç‰© |
| éª¨é«“æŠ‘åˆ¶é¢¨éšª | é«˜åº¦ï¼ˆè¡€å°æ¿æ¸›å°‘ç‚ºåŠ‘é‡é™åˆ¶æ¯’æ€§ï¼‰ |
| è‡´åæ€§åˆ†ç´š | ä¸­åº¦è‡³é«˜åº¦ |
| ç›£æ¸¬é …ç›® | CBCï¼ˆå«åˆ†é¡ï¼‰ã€è…åŠŸèƒ½ï¼ˆè‚Œé…¸é…æ¸…é™¤ç‡ï¼‰ã€é›»è§£è³ª |
| è™•ç½®é˜²è­· | éœ€ä¾ç´°èƒæ¯’æ€§è—¥ç‰©è™•ç½®è¦ç¯„æ“ä½œ |

## å®‰å…¨æ€§è€ƒé‡

**é‡è¦è­¦èª**ï¼š
- Carboplatin ä¸»è¦ç¶“è…è‡Ÿæ’æ³„ï¼Œè…åŠŸèƒ½ä¸å…¨æ‚£è€…éœ€èª¿æ•´åŠ‘é‡
- éª¨é«“æŠ‘åˆ¶ç‚ºä¸»è¦æ¯’æ€§ï¼Œéœ€å®šæœŸç›£æ¸¬è¡€çƒè¨ˆæ•¸
- å¯èƒ½å¼•èµ·éæ•åæ‡‰ï¼Œå°¤å…¶æ˜¯å¤šæ¬¡ä½¿ç”¨å¾Œ

**è—¥ç‰©äº¤äº’ä½œç”¨**ï¼š
- èˆ‡å…¶ä»–éª¨é«“æŠ‘åˆ¶è—¥ç‰©ä½µç”¨å¯èƒ½å¢åŠ è¡€æ¶²æ¯’æ€§
- èˆ‡è…æ¯’æ€§è—¥ç‰©ï¼ˆå¦‚ aminoglycoside æŠ—ç”Ÿç´ ï¼‰ä½µç”¨éœ€è¬¹æ…
- é¿å…èˆ‡æ´»æ€§ç–«è‹—åŒæ™‚ä½¿ç”¨

### è—¥ç‰©-é£Ÿç‰©äº¤äº’ä½œç”¨ (DFI)

**è‘¡è„æŸš** ğŸŸ¢ Minor
- å½±éŸ¿ï¼šè‘¡è„æŸšå°é‰‘é¡åŒ–ç™‚è—¥å½±éŸ¿è¼ƒå°
- å»ºè­°ï¼šç„¡éœ€ç‰¹åˆ¥é™åˆ¶


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**Peripheral Nervous System Diseases** ğŸ”´ Major
- æ³¨æ„äº‹é …ï¼šMild peripheral neuropathy has been noted during carboplatin therapy and is characterized most frequently by paresthesias...

**Infections** ğŸŸ¢ Minor
- æœ¬è—¥ç‰©åœ¨æ­¤æƒ…æ³ä¸‹ç¦ç”¨ã€‚éœ€å®šæœŸç›£æ¸¬ã€‚é¢¨éšªåŒ…æ‹¬ï¼šéª¨é«“æŠ‘åˆ¶ã€æ„ŸæŸ“ã€‚

**Hemorrhagic Disorders** ğŸŸ¢ Minor
- æœ¬è—¥ç‰©åœ¨æ­¤æƒ…æ³ä¸‹ç¦ç”¨ã€‚éœ€å®šæœŸç›£æ¸¬ã€‚é¢¨éšªåŒ…æ‹¬ï¼šéª¨é«“æŠ‘åˆ¶ã€å‡ºè¡€ã€è¡€æ “ã€‚å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚

**Bone Marrow Failure Disorders** ğŸŸ¢ Minor
- æœ¬è—¥ç‰©åœ¨æ­¤æƒ…æ³ä¸‹ç¦ç”¨ã€‚éœ€å®šæœŸç›£æ¸¬ã€‚é¢¨éšªåŒ…æ‹¬ï¼šéª¨é«“æŠ‘åˆ¶ã€å‡ºè¡€ã€æ„ŸæŸ“ã€è¡€æ “ã€è²§è¡€ã€‚å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚

**è…è‡Ÿç–¾ç—…** ğŸŸ¢ Minor
- éœ€å®šæœŸç›£æ¸¬ã€‚é¢¨éšªåŒ…æ‹¬ï¼šéª¨é«“æŠ‘åˆ¶ã€‚

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šProceed with Guardrails**

**ç†ç”±ï¼š**
Carboplatin åœ¨ä¹³è…ºç™Œæ²»ç™‚ä¸­å·²æœ‰å¤§é‡è‡¨åºŠè©¦é©—è­‰æ“šæ”¯æŒï¼Œå°¤å…¶åœ¨ä¸‰é™°æ€§ä¹³è…ºç™Œå’Œ BRCA çªè®Šç›¸é—œä¹³è…ºç™Œä¸­é¡¯ç¤ºè‰¯å¥½ç™‚æ•ˆã€‚å¤šé … Phase 2/3 è©¦é©—å·²å®Œæˆæˆ–æ­£åœ¨é€²è¡Œä¸­ã€‚

**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
- å¯†åˆ‡ç›£æ¸¬éª¨é«“æŠ‘åˆ¶å’Œè…åŠŸèƒ½
- é‡å°ç‰¹å®šåˆ†å­äºå‹ï¼ˆå¦‚ BRCA çªè®Šã€ä¸‰é™°æ€§ï¼‰çš„å€‹é«”åŒ–ç”¨è—¥ç­–ç•¥
- èˆ‡è…«ç˜¤ç§‘åœ˜éšŠå¯†åˆ‡åˆä½œï¼Œåˆ¶å®šé©ç•¶çš„ä½µç”¨æ–¹æ¡ˆ

---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Oteracil]({{ "/drugs/oteracil/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Gemcitabine]({{ "/drugs/gemcitabine/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Dronedarone]({{ "/drugs/dronedarone/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Hydroxyprogesterone Caproate]({{ "/drugs/hydroxyprogesterone_caproate/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Vonoprazan]({{ "/drugs/vonoprazan/" | relative_url }}) - è­‰æ“šç­‰ç´š L2

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Carboplatinè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/carboplatin/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_carboplatin,
  title = {Carboplatinè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/carboplatin/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
